Patients with abnormal numbers of CD3 + T cells had considerably higher mortality and recurrence rates. The immune system and especially the B cells of patients with acute lymphoblastic leukemia (ALL) ...

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

Researchers sought to determine the effects of multidisciplinary team-style continuity of care with nutritional nursing in patients with lung cancer receiving postoperative chemotherapy.

Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.

An intervention reduced the percentage of prior authorizations that were delayed or denied from 32% to 8%. A multi-pronged intervention reduced prior authorization delays and denials for patients ...

In a prospective longitudinal trial, researchers assessed the association between academic readiness and outcomes in patients who received brain tumor treatment in early childhood.

Ravi B Parikh, MD, MPP discusses the current and future use of artificial intelligence (AI) in the greater US health care ...

Data suggest that cabozantinib and pembrolizumab can be effective in patients with advanced gastric or gastroesophageal junction cancer whose disease is resistant or refractory to immune checkpoint ...

Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities, according to a study published online Oct. 29 in the ...

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

The median progression-free survival was 12.5 months in the treatment-naïve cohort and 5.5 months in the previously treated cohort. The researchers evaluated capmatinib in the phase 2 GEOMETRY mono-1 ...

Atezolizumab did not improve overall survival, progression-free survival, distant metastasis-free survival, or time to local failure.